GlassScriptPhysician profile
Carrie Barlow
NPI 1487832887
$1,634.06
in general payments reported to CMS, 2019-2025
28 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.00 · 2023: $268 · 2024: $629 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $204.13 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Novo Nordisk INC | $159.27 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $158.69 | 2023-2025 | Jardiance, Mounjaro, Baqsimi |
| Abbvie INC. | $137.94 | 2023-2025 | |
| Corcept Therapeutics | $92.47 | 2024-2025 | Korlym |
| Amgen INC. | $86.98 | 2024-2025 | Evenity, Tepezza, Repatha |
| Dexcom, INC. | $85.51 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $68.78 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $67.67 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alvogen INC | $59.19 | 2023-2025 | Teriparatide |
| Glaxosmithkline, LLC. | $49.01 | 2025 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $48.67 | 2025 | |
| Recordati_rare_diseases_inc. | $41.54 | 2025 | Isturisa |
| Insulet Corporation | $39.80 | 2024-2025 | Omnipod |
| Mannkind Corporation | $38.62 | 2023-2024 | Afrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $38.52 | 2025 | Twiist |
| Antares Pharma, INC. | $36.86 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $31.86 | 2024-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $29.60 | 2024-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.49 | 2024 | Jardiance |
| Radius Health, INC. | $18.80 | 2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $18.71 | 2024 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Ascendis Pharma Endocrinology INC | $17.28 | 2025 | Yorvipath |
| Acella Pharmaceuticals, LLC | $16.69 | 2023 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $14.98 | 2025 | Lokelma |
| Shield Therapeutics INC | $14.57 | 2024 | |
| Astellas Pharma US INC | $14.43 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.